Tandem Diabetes Care Q4 Revenue Rises 15%; Full-Year Guidance 50% Below Forecasts
Tandem Diabetes Care generated Q4 revenue of $290.4 million (15% y/y), topping consensus by 5%, and posted a GAAP loss of $0.01 per share versus a $0.06 expected loss, lifting operating margin to 2.9%. Full-year revenue guidance of $543 million trails analyst forecasts by 50%.
1. Q4 Financial Results
Tandem Diabetes Care posted Q4 revenue of $290.4 million, up 15% year over year and about 5% above analyst expectations. The company reported a GAAP loss of $0.01 per share versus an expected $0.06 loss, driving adjusted EBITDA of $32.9 million and an operating margin of 2.9%.
2. Annual Guidance Shortfall
Tandem Diabetes Care set full-year revenue guidance at $543 million, which is roughly 50% below consensus forecasts, highlighting a significant gap between company projections and analyst expectations.
3. Margin and Profitability Trends
The company delivered an adjusted EBITDA margin of 11.3% and achieved its first positive operating margin in over a year, reflecting improved cost efficiency and margin expansion compared to a -0.2% operating margin in the prior year period.
4. Market Reaction and Outlook
Shares have declined 13.8% year to date. Analysts forecast revenue growth of 8.4% next year and expect GAAP losses to narrow, but the sharp guidance miss may weigh on near-term investor sentiment.